Why Rite Aid Is the Wrong Play
Unimpressive second-quarter -- especially compared to Walgreen's profits.
Asian stocks took a hit overnight. The Hang Seng was off 0.13% and the Nikkei was down 2.64%. European stocks, however, were mixed earlier this morning. And here in the US, we're currently trading lower.
Here's what I'm focused on (other than the approaching weekend):
Rite Aid (RAD):
I continue to pay attention to the large drugstore chain for a couple of reasons. First, I always like to think it might give me some insight into how some of the other big chains (ala Walgreen (WAG) and CVS (CVS)) are doing. Second, I believe in the old investor theory that says our aging population will lead to increased demand for medicines and other health-related items. So I'm hoping the company can right this ship
That said, I should point out that the company's second-quarter results left me rather unimpressed.
1. In the period, the Street was looking for a $0.16 loss and the company lost $0.14. It's just hard to get excited about this, given the profits Walgreen has and is expected to turn in.
2. The downbeat outlook it offered up for fiscal 2010 didn't do much for me, either.
3. With the losses expected this year and next, what's in it for me if I get involved now?
Research In Motion (RIMM):
Did you see the "CrackBerry" company's second-quarter numbers that came out after the close last night?
Excluding items, it put up $1.03, whereas the Street had been looking for a buck. However, the talk this morning is likely going to be about two things: First, it missed on the top line, and second, for the third quarter, it indicated in the release it's looking for $3.6 to $3.85 billion on the top line. The issue there is that the Street is at $3.9 billion.
Meanwhile, on the bottom line, it's looking for $1 to $1.08. And that's fairly underwhelming because the estimate is $1.04.
Some other thoughts:
1. Admittedly, the expectations bar was set pretty high, given the beats it turned in both in the fourth quarter of last year and the first quarter of this year. However, the shares do deserve a backhanded slap. I'm concerned that some of the excitement and cult-like mentality that's been surrounding the stock could peter off.
2. The shares trade at about 20.1 times this year's estimate of $4.13, which is just too much. I'm not saying its definitely going to get down to this level, but I'd be more interested in the high $60s or low $70s. Again, I think there will be a pullback early in the session.
Minyan Justin points out in Upgrades & Downgrades: Red Ink for Research in Motion? that Deutsche downgraded the company.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter